Explore more publications!
Health Update Bahamas
Submit Press Release

Health Update Bahamas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Update Bahamas.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on September 15, 2025

Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
September 15, 2025

Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease

Indeterminate GlobeNewswire
KFSHRC Reduces Emergency Department Inpatient Bed Waiting Time by 75%
September 15, 2025

KFSHRC Reduces Emergency Department Inpatient Bed Waiting Time by 75%

Indeterminate GlobeNewswire
Request for Secretary of State of Texas, Jane Nelson, to Organize a Public Meeting Between Crosetto and CPRIT Scientists Who Have Allocated $3.65 Billion of $6 Billion to Cancer Research
September 15, 2025

Request for Secretary of State of Texas, Jane Nelson, to Organize a Public Meeting Between Crosetto and CPRIT Scientists Who Have Allocated $3.65 Billion of $6 Billion to Cancer Research

Indeterminate GlobeNewswire
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
September 15, 2025

Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Indeterminate GlobeNewswire
Avalyn to Highlight AURA-IPF Phase 2 Clinical Trial Design for AP02, Inhaled Nintedanib, at the European Respiratory Society International Congress 2025
September 15, 2025

Avalyn to Highlight AURA-IPF Phase 2 Clinical Trial Design for AP02, Inhaled Nintedanib, at the European Respiratory Society International Congress 2025

Indeterminate GlobeNewswire
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
September 15, 2025

INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult

Indeterminate GlobeNewswire
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
September 15, 2025

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Indeterminate GlobeNewswire
Extendicare Announces September 2025 Dividend of C$0.042 per Share
September 15, 2025

Extendicare Announces September 2025 Dividend of C$0.042 per Share

Indeterminate GlobeNewswire
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
September 15, 2025

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors

Indeterminate GlobeNewswire
Excision BioTherapeutics Announces Positive Preclinical Data Highlighting the Safety, Potency and Development Progress of the Hepatitis B EBT-107 Program at the ICE-HBV “Hepatitis B Cure Symposium”
September 15, 2025

Excision BioTherapeutics Announces Positive Preclinical Data Highlighting the Safety, Potency and Development Progress of the Hepatitis B EBT-107 Program at the ICE-HBV “Hepatitis B Cure Symposium”

Indeterminate GlobeNewswire
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
September 15, 2025

Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases

Indeterminate GlobeNewswire
Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
September 15, 2025

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Indeterminate GlobeNewswire
Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador
September 15, 2025

Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador

Indeterminate GlobeNewswire
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds
September 15, 2025

Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds

Indeterminate GlobeNewswire
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer
September 15, 2025

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Indeterminate GlobeNewswire
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
September 15, 2025

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Indeterminate GlobeNewswire
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
September 15, 2025

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

Indeterminate GlobeNewswire
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
September 15, 2025

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

Indeterminate GlobeNewswire
Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer
September 15, 2025

Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer

Indeterminate GlobeNewswire
Harrow Announces Agenda and Speakers for Investor & Analyst Day
September 15, 2025

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions